Neuroelectrics

Neuroelectrics develops personalized brain monitoring and stimulation technologies for treating neurological disorders through cloud-based neuromodulation. The company's Starstim platform integrates a wireless headpiece for EEG monitoring and multi-channel transcranial Electrical Stimulation (tES), cloud-based secure remote treatment delivery, and personalization protocols based on neuroscience research and patient physiological data. Neuroelectrics is conducting a pivotal trial in refractory focal epilepsy and a pilot study in at-home treatment of depression. The platform is also used by hundreds of researchers with hundreds of published papers. Founded in 2011 and headquartered in Barcelona, Spain, the company has raised approximately $17.9M in Series A funding. Neuroelectrics differentiates itself through its novel neurocircuit therapeutics approach that identifies dysfunctional neural networks and targets them holistically, offering a non-invasive, non-drug option for patients whose conditions have not been controlled by medications or surgery.